Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Ou connectez-vous avec votre réseau social favori

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

Gabather AB

Gabather AB_logo
5
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Södertälje, STOCKHOLM, Sweden

Send a message

Anglais

Gabather AB

Anglais

Gabather AB is a Swedish Pharma/Biotech Company focused on the development of novel medicines for the treatment of metal disorders with high unmet medical need, such as schizophrenia. Our most advanced compound GT-002 is a novel first in class agent targeting three central aspects of mental disorders; i) inhibits psychosis; ii) improves memory and cognition and iii) promotes social interaction counteracting the debilitating social withdrawal accompanying many central...

See more

Gabather AB is a Swedish Pharma/Biotech Company focused on the development of novel medicines for the treatment of metal disorders with high unmet medical need, such as schizophrenia. Our most advanced compound GT-002 is a novel first in class agent targeting three central aspects of mental disorders; i) inhibits psychosis; ii) improves memory and cognition and iii) promotes social interaction counteracting the debilitating social withdrawal accompanying many central nervous system (CNS) diseases. This differentiates GT-002 from all other therapies on the market, which are only able to target a limited range of symptoms in e.g. schizophrenia focusing primarily on psychosis and other associated positive symptoms. GT-002 is currently in clinical phase I development and targeted for proof of concept (POC) clinical studies in patients during 2020.

The commercialisation strategy is to develop GT-002 to clinical Phase II POC and thereafter acquire strategic partners for continued clinical development and market launch.

Gabather aims to gain global recognition as an emerging knowledge centre for treatment of schizophrenia and then expand to other mental disorders, including autism spectrum disorder (ASD), bipolar disorder, attentional deficit hyperactivity disorder (ADHD), Alzheimer’s disease (AD) and Down syndrome.

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1012 Entities

Communities